{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:28:27Z","timestamp":1794853707352,"version":"4.9.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000381","name":"Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["129"],"award-info":[{"award-number":["129"]}],"id":[{"id":"10.13039\/501100000381","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In multiple sclerosis (MS), progressive disability occurs following degeneration of demyelinated axons. A tractable approach to delay, prevent or reverse disability progression is through enhancement of endogenous remyelination. Clinical trials have deployed drugs, such as clemastine, to target the rate-limiting step in this process: differentiation of oligodendrocyte progenitor cells (OPCs). Preclinical research has shown that metformin can reverse an age-associated deficit in the responsiveness of OPCs to pro-differentiation factors. The purpose of the Cambridge Centre for Myelin Repair trial Two (CCMR Two) is to evaluate the efficacy of the combination of metformin and clemastine to promote remyelination in people with MS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants with relapsing-remitting MS (RRMS) will be randomised 1:1 to the combination of metformin and clemastine or matched placebos and followed for 24\u00a0weeks of treatment. All participants must be stable on a disease-modifying therapy and have evidence of chronic stable optic neuropathy in at least one eye (defined by P100 latency of the visual evoked potential (VEP)\u2009\u2265\u2009118\u00a0ms, and the absence of a history of acute optic neuritis in the preceding 2 years). The primary outcome measure will be the change in the P100 latency of the full-field VEP between baseline and week 26. It is planned to recruit a total of 70 participants. This will have 80% power to detect a reduction of 3\u00a0ms in VEP P100 latency between the two treatment groups. Secondary outcome measures will examine the change in multifocal VEP and the change in lesional magnetisation transfer ratio (MTR) for lesions stratified by location and tissue-specific cohort baseline lesional MTR values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>We set out the trial design, the rationale for participant and outcome measure selection, and the pre-specified analyses. With this trial, we expect to be able to detect the structural and functional consequences of remyelination within a sample size feasible for our single-centre trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT05131828, prior to participant enrolment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-09254-2","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T10:35:24Z","timestamp":1765190124000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7688-7638","authenticated-orcid":false,"given":"Gioia","family":"Riboni-Verri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8710-0930","authenticated-orcid":false,"given":"Christopher E.","family":"McMurran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4058-0030","authenticated-orcid":false,"given":"Trisha","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2329-5329","authenticated-orcid":false,"given":"Cyrus","family":"Daruwalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6239-4306","authenticated-orcid":false,"given":"Jonathon","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riddhima","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-0186","authenticated-orcid":false,"given":"Benson S.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Cutting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4238-3471","authenticated-orcid":false,"given":"Wendi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"MacManus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3076-2682","authenticated-orcid":false,"given":"Declan T.","family":"Chard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7737-5834","authenticated-orcid":false,"given":"J. William L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4738-0760","authenticated-orcid":false,"given":"Alasdair J.","family":"Coles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7562-2838","authenticated-orcid":false,"given":"Nick G.","family":"Cunniffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"9254_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/978-981-32-9636-7_14","volume":"1190","author":"R Yamasaki","year":"2019","unstructured":"Yamasaki R, Kira JI. Multiple Sclerosis. Adv Exp Med Biol. 2019;1190:217\u201347.","journal-title":"Adv Exp Med Biol"},{"issue":"9648","key":"9254_CR2","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502\u201317.","journal-title":"Lancet"},{"key":"9254_CR3","unstructured":"The Multiple Sclerosis International Federation Atlas of MS, 3rd ed. 2020. https:\/\/www.atlasofms.org."},{"issue":"1","key":"9254_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41582-018-0082-z","volume":"15","author":"M Tintore","year":"2019","unstructured":"Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis \u2014 success from bench to bedside. Nat Rev Neurol. 2019;15(1):53\u20138.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"9254_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","volume":"15","author":"N Scolding","year":"2015","unstructured":"Scolding N, Barnes D, Cader S, Chataway J, Chaudhuri A, Coles A, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15(4):273\u20139.","journal-title":"Pract Neurol"},{"issue":"12","key":"9254_CR6","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41573-019-0035-2","volume":"18","author":"S Faissner","year":"2019","unstructured":"Faissner S, Plemel JR, Gold R, Yong VW. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nat Rev Drug Discov. 2019;18(12):905\u201322.","journal-title":"Nat Rev Drug Discov"},{"key":"9254_CR7","doi-asserted-by":"crossref","unstructured":"Cunniffe N, Vuong KA, Ainslie D, Baker D, Beveridge J, Bickley S, Camilleri P, Craner M, Fitzgerald D, de la Fuente AG et al. Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis. J Neurol, Neurosurg & Psychiatry. 2020:jnnp-2020\u2013324286.","DOI":"10.1136\/jnnp-2020-324286"},{"key":"9254_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09421-x","author":"N Cunniffe","year":"2019","unstructured":"Cunniffe N, Coles A. Promoting remyelination in multiple sclerosis. J Neurol. 2019. https:\/\/doi.org\/10.1007\/s00415-019-09421-x.","journal-title":"J Neurol"},{"issue":"6","key":"9254_CR9","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/brain\/awn080","volume":"131","author":"KA Irvine","year":"2008","unstructured":"Irvine KA, Blakemore WF. Remyelination protects axons from demyelination-associated axon degeneration. Brain. 2008;131(6):1464\u201377.","journal-title":"Brain"},{"issue":"7399","key":"9254_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nature11007","volume":"485","author":"U F\u00fcnfschilling","year":"2012","unstructured":"F\u00fcnfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature. 2012;485(7399):517\u201321.","journal-title":"Nature"},{"issue":"12","key":"9254_CR11","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.tcb.2013.07.007","volume":"23","author":"BM Morrison","year":"2013","unstructured":"Morrison BM, Lee Y, Rothstein JD. Oligodendroglia: metabolic supporters of axons. Trends Cell Biol. 2013;23(12):644\u201351.","journal-title":"Trends Cell Biol"},{"issue":"7408","key":"9254_CR12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature11314","volume":"487","author":"Y Lee","year":"2012","unstructured":"Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature. 2012;487(7408):443\u20138.","journal-title":"Nature"},{"key":"9254_CR13","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.18246","volume":"5","author":"F Mei","year":"2016","unstructured":"Mei F, Lehmann-Horn K, Shen Y-AA, Rankin KA, Stebbins KJ, Lorrain DS, et al. Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery. Elife. 2016;5:e18246.","journal-title":"Elife"},{"issue":"8","key":"9254_CR14","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S1474-4422(20)30140-X","volume":"19","author":"C Lubetzki","year":"2020","unstructured":"Lubetzki C, Zalc B, Williams A, Stadelmann C, Stankoff B. Remyelination in multiple sclerosis: from basic science to clinical translation. Lancet Neurol. 2020;19(8):678\u201388.","journal-title":"Lancet Neurol"},{"issue":"12","key":"9254_CR15","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1093\/brain\/awl217","volume":"129","author":"P Patrikios","year":"2006","unstructured":"Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain. 2006;129(12):3165\u201372.","journal-title":"Brain"},{"issue":"22","key":"9254_CR16","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181a8260a","volume":"72","author":"T Goldschmidt","year":"2009","unstructured":"Goldschmidt T, Antel J, K\u00f6nig FB, Br\u00fcck W, Kuhlmann T. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology. 2009;72(22):1914\u201321.","journal-title":"Neurology"},{"issue":"12","key":"9254_CR17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/nrn.2017.136","volume":"18","author":"RJM Franklin","year":"2017","unstructured":"Franklin RJM, ffrench-Constant C. Regenerating CNS myelin \u2014 from mechanisms to experimental medicines. Nat Rev Neurosci. 2017;18(12):753\u201369.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"9254_CR18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.mcn.2003.10.014","volume":"25","author":"RH Woodruff","year":"2004","unstructured":"Woodruff RH, Fruttiger M, Richardson WD, Franklin RJM. Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination. Mol Cell Neurosci. 2004;25(2):252\u201362.","journal-title":"Mol Cell Neurosci"},{"issue":"6","key":"9254_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00401-013-1112-y","volume":"125","author":"A Boyd","year":"2013","unstructured":"Boyd A, Zhang H, Williams A. Insufficient OPC migration into demyelinated lesions is a cause of poor remyelination in MS and mouse models. Acta Neuropathol. 2013;125(6):841\u201359.","journal-title":"Acta Neuropathol"},{"issue":"7471","key":"9254_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature12647","volume":"502","author":"VA Deshmukh","year":"2013","unstructured":"Deshmukh VA, Tardif V, Lyssiotis CA, Green CC, Kerman B, Kim HJ, et al. A regenerative approach to the treatment of multiple sclerosis. Nature. 2013;502(7471):327\u201332.","journal-title":"Nature"},{"issue":"8","key":"9254_CR21","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/nm.3618","volume":"20","author":"F Mei","year":"2014","unstructured":"Mei F, Fancy SPJ, Shen Y-AA, Niu J, Zhao C, Presley B, et al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat Med. 2014;20(8):954\u201360.","journal-title":"Nat Med"},{"issue":"7555","key":"9254_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/nature14335","volume":"522","author":"FJ Najm","year":"2015","unstructured":"Najm FJ, Madhavan M, Zaremba A, Shick E, Karl RT, Factor DC, et al. Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo. Nature. 2015;522(7555):216\u201320.","journal-title":"Nature"},{"issue":"10111","key":"9254_CR23","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","volume":"390","author":"AJ Green","year":"2017","unstructured":"Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017;390(10111):2481\u20139.","journal-title":"Lancet"},{"issue":"3","key":"9254_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(16)30377-5","volume":"16","author":"D Cadavid","year":"2017","unstructured":"Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16(3):189\u201399.","journal-title":"Lancet Neurol"},{"issue":"9","key":"9254_CR25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S1474-4422(19)30137-1","volume":"18","author":"D Cadavid","year":"2019","unstructured":"Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulovi\u0107 J, et al. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019;18(9):845\u201356.","journal-title":"Lancet Neurol"},{"issue":"2","key":"9254_CR26","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00415-016-8341-7","volume":"264","author":"CJ Schwartzbach","year":"2017","unstructured":"Schwartzbach CJ, Grove RA, Brown R, Tompson D, Then Bergh F, Arnold DL. Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study. J Neurol. 2017;264(2):304\u201315.","journal-title":"J Neurol"},{"issue":"9","key":"9254_CR27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S1474-4422(21)00179-4","volume":"20","author":"JWL Brown","year":"2021","unstructured":"Brown JWL, Cunniffe NG, Prados F, Kanber B, Jones JL, Needham E, et al. Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR one): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. Lancet Neurol. 2021;20(9):709\u201320.","journal-title":"Lancet Neurol"},{"issue":"1","key":"9254_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1177\/1352458508095731","volume":"15","author":"A Niklas","year":"2009","unstructured":"Niklas A, Sebraoui H, He\u00df E, Wagner A, Then Bergh F. Outcome measures for trials of remyelinating agents in multiple sclerosis: retrospective longitudinal analysis of visual evoked potential latency. Mult Scler J. 2009;15(1):68\u201374.","journal-title":"Mult Scler J"},{"issue":"1","key":"9254_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2023-000560","volume":"6","author":"G Riboni-Verri","year":"2024","unstructured":"Riboni-Verri G, Chen BS, McMurran CE, Halliwell GJ, Brown JWL, Coles AJ, et al. Visual outcome measures in clinical trials of remyelinating drugs. BMJ Neurology Open. 2024;6(1):e000560.","journal-title":"BMJ Neurology Open"},{"issue":"4","key":"9254_CR30","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.stem.2019.08.015","volume":"25","author":"B Neumann","year":"2019","unstructured":"Neumann B, Baror R, Zhao C, Segel M, Dietmann S, Rawji KS, et al. Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells. Cell Stem Cell. 2019;25(4):473-485.e478.","journal-title":"Cell Stem Cell"},{"issue":"7","key":"9254_CR31","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/acn3.51595","volume":"9","author":"CE McMurran","year":"2022","unstructured":"McMurran CE, Mukherjee T, Brown JWL, Michell AW, Chard DT, Franklin RJM, et al. Remyelination in humans due to a retinoid-X receptor agonist is age-dependent. Ann Clin Transl Neurol. 2022;9(7):1090\u20134.","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"9254_CR32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373.","journal-title":"Lancet Neurol"},{"issue":"5","key":"9254_CR33","doi-asserted-by":"publisher","first-page":"665","DOI":"10.7326\/M21-4389","volume":"175","author":"J Maarten","year":"2022","unstructured":"Maarten J, Wensink YL. Lu Tian: Preconception Antidiabetic Drugs in Men and Birth Defects in Offspring. Ann Intern Med. 2022;175(5):665\u201373.","journal-title":"Ann Intern Med"},{"issue":"6","key":"9254_CR34","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ana.20851","volume":"59","author":"F Costello","year":"2006","unstructured":"Costello F, Coupland S, Hodge W, Lorello GR, Koroluk J, Pan YI, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol. 2006;59(6):963\u20139.","journal-title":"Ann Neurol"},{"issue":"4","key":"9254_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000135","volume":"2","author":"SL Galetta","year":"2015","unstructured":"Galetta SL, Villoslada P, Levin N, Shindler K, Ishikawa H, Parr E, et al. Acute optic neuritis. Unmet clinical needs and model for new therapies. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e135.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"Pt 3","key":"9254_CR36","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/brain\/124.3.468","volume":"124","author":"A Brusa","year":"2001","unstructured":"Brusa A, Jones SJ, Plant GT. Long-term remyelination after optic neuritis: a 2-year visual evoked potential and psychophysical serial study. Brain. 2001;124(Pt 3):468\u201379.","journal-title":"Brain"},{"issue":"20","key":"9254_CR37","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1212\/WNL.0b013e3182929fd5","volume":"80","author":"L Horton","year":"2013","unstructured":"Horton L, Conger A, Conger D, Remington G, Frohman T, Frohman E, et al. Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy. Neurology. 2013;80(20):1862\u20136.","journal-title":"Neurology"},{"issue":"6","key":"9254_CR38","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/cns.13096","volume":"25","author":"KMS Kanhai","year":"2019","unstructured":"Kanhai KMS, Nij Bijvank JA, Wagenaar YL, Klaassen ES, Lim K, Bergheanu SC, et al. Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: a randomized double-blind, placebo-controlled cross-over trial. CNS Neurosci Ther. 2019;25(6):697\u2013703.","journal-title":"CNS Neurosci Ther"},{"issue":"3","key":"9254_CR39","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1042\/BJ20150497","volume":"471","author":"R Pryor","year":"2015","unstructured":"Pryor R, Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J. 2015;471(3):307\u201322.","journal-title":"Biochem J"},{"issue":"6","key":"9254_CR40","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1042\/CS20110386","volume":"122","author":"B Viollet","year":"2011","unstructured":"Viollet B, Guigas B, Garcia NS, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci. 2011;122(6):253\u201370.","journal-title":"Clin Sci"},{"issue":"12","key":"9254_CR41","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.2337\/diabetes.49.12.2063","volume":"49","author":"RS Hundal","year":"2000","unstructured":"Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000;49(12):2063\u20139.","journal-title":"Diabetes"},{"issue":"12","key":"9254_CR42","doi-asserted-by":"publisher","first-page":"8005","DOI":"10.4049\/jimmunol.0803563","volume":"182","author":"N Nath","year":"2009","unstructured":"Nath N, Khan M, Paintlia MK, Hoda MN, Giri S. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J Immunol. 2009;182(12):8005\u201314.","journal-title":"J Immunol"},{"issue":"5","key":"9254_CR43","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1001\/jamaneurol.2015.4807","volume":"73","author":"L Negrotto","year":"2016","unstructured":"Negrotto L, Farez MF, Correale J. Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis. JAMA Neurol. 2016;73(5):520\u20138.","journal-title":"JAMA Neurol"},{"issue":"3","key":"9254_CR44","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3132\/dvdr.2008.027","volume":"5","author":"JH Scarpello","year":"2008","unstructured":"Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diabetes Vasc Dis Res. 2008;5(3):157\u201367.","journal-title":"Diabetes Vasc Dis Res"},{"issue":"4","key":"9254_CR45","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/14746514040040041101","volume":"4","author":"J Davidson","year":"2004","unstructured":"Davidson J, Howlett H. New prolonged-release metformin improves gastrointestinal tolerability. Br J Diabetes Vasc Dis. 2004;4(4):273\u20137.","journal-title":"Br J Diabetes Vasc Dis"},{"issue":"4","key":"9254_CR46","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1185\/030079904125003278","volume":"20","author":"L Blonde","year":"2004","unstructured":"Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin. 2004;20(4):565\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"9254_CR47","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/14746514070070050501","volume":"7","author":"MD Feher","year":"2007","unstructured":"Feher MD, Al-Mrayat Me, Brake J, Leong KS. Tolerability of prolonged-release metformin (Glucophage\u00ae SR) in individuals intolerant to standard metformin \u2014 results from four UK centres. Br J Diabetes Vasc Dis. 2007;7(5):225\u20138.","journal-title":"Br J Diabetes Vasc Dis"},{"issue":"6","key":"9254_CR48","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2165\/00002018-199920060-00003","volume":"20","author":"DHCS Howlett","year":"1999","unstructured":"Howlett DHCS, Bailey CJ. A risk-benefit assessment of Metformin in type 2 diabetes mellitus. Drug Saf. 1999;20(6):489\u2013503.","journal-title":"Drug Saf"},{"key":"9254_CR49","unstructured":"Administration UFD: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers In. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers; 2005."},{"issue":"7758","key":"9254_CR50","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/S0140-6736(72)91155-5","volume":"1","author":"AM Halliday","year":"1972","unstructured":"Halliday AM, McDonald WI, Mushin J. Delayed visual evoked response in optic neuritis. Lancet. 1972;1(7758):982\u20135.","journal-title":"Lancet"},{"issue":"4","key":"9254_CR51","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/0013-4694(83)90131-1","volume":"55","author":"C Yiannikas","year":"1983","unstructured":"Yiannikas C, Walsh JC. The variation of the pattern shift visual evoked response with the size of the stimulus field. Electroencephalogr Clin Neurophysiol. 1983;55(4):427\u201335.","journal-title":"Electroencephalogr Clin Neurophysiol"},{"issue":"5","key":"9254_CR52","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3109\/01658107.2015.1074253","volume":"39","author":"D Alshowaeir","year":"2015","unstructured":"Alshowaeir D, Yiannikas C, Klistorner A. Multifocal visual evoked potential (mfVEP) and pattern-reversal visual evoked potential changes in patients with visual pathway disorders: a case series. Neuro-Ophthalmology. 2015;39(5):220\u201333.","journal-title":"Neuro-Ophthalmology"},{"issue":"1","key":"9254_CR53","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/BF00236791","volume":"35","author":"D Lehmann","year":"1979","unstructured":"Lehmann D, Skrandies W. Multichannel evoked potential fields show different properties of human upper and lower hemiretina systems. Exp Brain Res. 1979;35(1):151\u20139.","journal-title":"Exp Brain Res"},{"issue":"6","key":"9254_CR54","first-page":"937","volume":"39","author":"AI Klistorner","year":"1998","unstructured":"Klistorner AI, Graham SL, Grigg JR, Billson FA. Multifocal topographic visual evoked potential: improving objective detection of local visual field defects. Invest Ophthalmol Vis Sci. 1998;39(6):937\u201350.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9254_CR55","doi-asserted-by":"publisher","DOI":"10.1097\/00041327-200312000-00010","author":"DC Hood","year":"2003","unstructured":"Hood DC, Odel JG, Winn BJ. The multifocal visual evoked potential. J Neuro-Ophthalmol. 2003. https:\/\/doi.org\/10.1097\/00041327-200312000-00010.","journal-title":"J Neuro-Ophthalmol"},{"issue":"5","key":"9254_CR56","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1167\/iovs.09-4577","volume":"51","author":"A Klistorner","year":"2010","unstructured":"Klistorner A, Arvind H, Garrick R, Graham SL, Paine M, Yiannikas C. Interrelationship of optical coherence tomography and multifocal visual-evoked potentials after optic neuritis. Invest Ophthalmol Vis Sci. 2010;51(5):2770\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"9254_CR57","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.clinph.2017.03.047","volume":"128","author":"G Pihl-Jensen","year":"2017","unstructured":"Pihl-Jensen G, Schmidt MF, Frederiksen JL. Multifocal visual evoked potentials in optic neuritis and multiple sclerosis: a review. Clin Neurophysiol. 2017;128(7):1234\u201345.","journal-title":"Clin Neurophysiol"},{"issue":"12","key":"9254_CR58","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s40263-018-0575-8","volume":"32","author":"A Klistorner","year":"2018","unstructured":"Klistorner A, Chai Y, Leocani L, Albrecht P, Aktas O, Butzkueven H, et al. Assessment of opicinumab in acute optic neuritis using multifocal visual evoked potential. CNS Drugs. 2018;32(12):1159\u201371.","journal-title":"CNS Drugs"},{"issue":"3","key":"9254_CR59","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/ana.20202","volume":"56","author":"K Schmierer","year":"2004","unstructured":"Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol. 2004;56(3):407\u201315.","journal-title":"Ann Neurol"},{"issue":"2","key":"9254_CR60","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1750-3639.2006.00043.x","volume":"17","author":"M Albert","year":"2007","unstructured":"Albert M, Antel J, Br\u00fcck W, Stadelmann C. Extensive cortical remyelination in patients with chronic multiple sclerosis. Brain Pathol. 2007;17(2):129\u201338.","journal-title":"Brain Pathol"},{"issue":"6","key":"9254_CR61","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/ana.23693","volume":"72","author":"A Chang","year":"2012","unstructured":"Chang A, Staugaitis SM, Dutta R, Batt CE, Easley KE, Chomyk AM, et al. Cortical remyelination: a new target for repair therapies in multiple sclerosis. Ann Neurol. 2012;72(6):918\u201326.","journal-title":"Ann Neurol"},{"issue":"5","key":"9254_CR62","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/jnen\/nlx023","volume":"76","author":"EMM Strijbis","year":"2017","unstructured":"Strijbis EMM, Kooi E-J, van der Valk P, Geurts JJG. Cortical remyelination is heterogeneous in multiple sclerosis. J Neuropathol Exp Neurol. 2017;76(5):390\u2013401.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"10","key":"9254_CR63","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/acn3.51662","volume":"9","author":"JWL Brown","year":"2022","unstructured":"Brown JWL, Prados F, Altmann DR, Kanber B, Stutters J, Cunniffe NG, et al. Remyelination varies between and within lesions in multiple sclerosis following bexarotene. Ann Clin Transl Neurol. 2022;9(10):1626\u201342.","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"9254_CR64","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/ncpneuro0950","volume":"4","author":"EM Frohman","year":"2008","unstructured":"Frohman EM, Fujimoto JG, Frohman TC, Calabresi PA, Cutter G, Balcer LJ. Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol. 2008;4(12):664\u201375.","journal-title":"Nat Clin Pract Neurol"},{"issue":"11","key":"9254_CR65","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrneurol.2015.174","volume":"11","author":"J Fielding","year":"2015","unstructured":"Fielding J, Clough M, Beh S, Millist L, Sears D, Frohman AN, et al. Ocular motor signatures of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol. 2015;11(11):637\u201345.","journal-title":"Nat Rev Neurol"},{"key":"9254_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.","journal-title":"BMJ"},{"issue":"1","key":"9254_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10633-016-9553-y","volume":"133","author":"JV Odom","year":"2016","unstructured":"Odom JV, Bach M, Brigell M, Holder GE, McCulloch DL, Mizota A, et al. ISCEV standard for clinical visual evoked potentials: (2016 update). Doc Ophthalmol. 2016;133(1):1\u20139.","journal-title":"Doc Ophthalmol"},{"issue":"1","key":"9254_CR68","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1148\/radiol.2361040450","volume":"236","author":"JJG Geurts","year":"2005","unstructured":"Geurts JJG, Pouwels PJW, Uitdehaag BMJ, Polman CH, Barkhof F, Castelijns JA. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology. 2005;236(1):254\u201360.","journal-title":"Radiology"},{"issue":"11","key":"9254_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078879","volume":"8","author":"V Sethi","year":"2013","unstructured":"Sethi V, Muhlert N, Ron M, Golay X, Wheeler-Kingshott CA, Miller DH, et al. MS cortical lesions on DIR: not quite what they seem? PLoS ONE. 2013;8(11):e78879.","journal-title":"PLoS ONE"},{"issue":"4","key":"9254_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034823","volume":"7","author":"P Tewarie","year":"2012","unstructured":"Tewarie P, Balk L, Costello F, Green A, Martin R, Schippling S, et al. The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS ONE. 2012;7(4):e34823.","journal-title":"PLoS ONE"},{"key":"9254_CR71","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.neubiorev.2016.02.018","volume":"64","author":"I Noorani","year":"2016","unstructured":"Noorani I, Carpenter RH. The LATER model of reaction time and decision. Neurosci Biobehav Rev. 2016;64:229\u201351.","journal-title":"Neurosci Biobehav Rev"},{"issue":"7","key":"9254_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200695","volume":"13","author":"JA Nij Bijvank","year":"2018","unstructured":"Nij Bijvank JA, Petzold A, Balk LJ, Tan HS, Uitdehaag BMJ, Theodorou M, et al. A standardized protocol for quantification of saccadic eye movements: DEMoNS. PLoS ONE. 2018;13(7):e0200695\u2013e0200695.","journal-title":"PLoS ONE"},{"issue":"7","key":"9254_CR73","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-019-0574-1","volume":"21","author":"L Wooliscroft","year":"2019","unstructured":"Wooliscroft L, Silbermann E, Cameron M, Bourdette D. Approaches to remyelination therapies in multiple sclerosis. Curr Treat Options Neurol. 2019;21(7):34.","journal-title":"Curr Treat Options Neurol"},{"issue":"52","key":"9254_CR74","doi-asserted-by":"publisher","first-page":"27074","DOI":"10.1073\/pnas.1906358116","volume":"116","author":"M Heidari","year":"2019","unstructured":"Heidari M, Radcliff AB, McLellan GJ, Ver Hoeve JN, Chan K, Kiland JA, et al. Evoked potentials as a biomarker of remyelination. Proc Natl Acad Sci U S A. 2019;116(52):27074\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"9254_CR75","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1177\/1352458517690822","volume":"23","author":"LJ Balcer","year":"2017","unstructured":"Balcer LJ, Raynowska J, Nolan R, Galetta SL, Kapoor R, Benedict R, et al. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Mult Scler. 2017;23(5):734\u201347.","journal-title":"Mult Scler"},{"issue":"11","key":"9254_CR76","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nrneurol.2012.200","volume":"8","author":"RJM Franklin","year":"2012","unstructured":"Franklin RJM, ffrench-Constant C, Edgar JM, Smith KJ. Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol. 2012;8(11):624\u201334.","journal-title":"Nat Rev Neurol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09254-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09254-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09254-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T12:03:31Z","timestamp":1765195411000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09254-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9254"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09254-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6197547\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We obtained ethical approval from the East Midlands\u2013Nottingham 2 Research Ethics Committee (21\/EM\/0120). Written, informed consent to participate will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"The authors confirm that all individuals involved in this trial have provided their informed consent for publication. Copies of the informed consent form are included as a supplement.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The author(s) declared the following potential conflicts of interest with respect to the research, authorship and\/or publication of this article: GRV, CEM, TM, CD, RG, BC, EC, and WQ have nothing to disclose. DC reports consulting for Hoffmann-La Roche. In the last 3 years, he has received research funding from Hoffmann-La Roche, the MS Society, the Medical Research Council, and the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre. He has co-supervised a clinical fellowship at the National Hospital for Neurology and Neurosurgery, London, which was supported by Merck. JWLB reports consulting and lecture fees from The Corpus, Biogen Idec and Novartis. AJC and NGC report grants from the MS Society of GB during the conduct of the trial. NGC additionally reports consulting, lecture and conference fees for Sanofi, Merck, Lucid group, and Progentos therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"562"}}